GEP201706690B - Novel process for making compounds for use in treatment of cancer - Google Patents

Novel process for making compounds for use in treatment of cancer

Info

Publication number
GEP201706690B
GEP201706690B GEAP201313824A GEAP2013013824A GEP201706690B GE P201706690 B GEP201706690 B GE P201706690B GE AP201313824 A GEAP201313824 A GE AP201313824A GE AP2013013824 A GEAP2013013824 A GE AP2013013824A GE P201706690 B GEP201706690 B GE P201706690B
Authority
GE
Georgia
Prior art keywords
cancer
treatment
novel process
making compounds
compounds
Prior art date
Application number
GEAP201313824A
Other languages
English (en)
Inventor
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
C Gregory Sowell
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Genentech Inc filed Critical Exelixis Inc
Publication of GEP201706690B publication Critical patent/GEP201706690B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GEAP201313824A 2012-10-12 2013-10-14 Novel process for making compounds for use in treatment of cancer GEP201706690B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
GEP201706690B true GEP201706690B (en) 2017-06-26

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201313824A GEP201706690B (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in treatment of cancer

Country Status (31)

Country Link
US (4) US9771347B2 (forum.php)
EP (1) EP2909188B1 (forum.php)
JP (2) JP6300042B2 (forum.php)
KR (1) KR102204520B1 (forum.php)
CN (2) CN108948043B (forum.php)
AU (1) AU2013328929B2 (forum.php)
BR (1) BR112015008113B1 (forum.php)
CA (1) CA2889466C (forum.php)
CL (1) CL2015000926A1 (forum.php)
CR (2) CR20200237A (forum.php)
EA (1) EA030613B1 (forum.php)
ES (1) ES2671502T3 (forum.php)
GE (1) GEP201706690B (forum.php)
HK (1) HK1213567A1 (forum.php)
HR (1) HRP20180670T1 (forum.php)
IL (1) IL238116B (forum.php)
IN (1) IN2015DN03928A (forum.php)
MA (1) MA38085B1 (forum.php)
MX (2) MX372708B (forum.php)
MY (1) MY186549A (forum.php)
NZ (1) NZ706723A (forum.php)
PE (3) PE20191818A1 (forum.php)
PH (1) PH12015500785B1 (forum.php)
PL (1) PL2909188T3 (forum.php)
SA (1) SA515360271B1 (forum.php)
SG (1) SG11201502795VA (forum.php)
SI (1) SI2909188T1 (forum.php)
TR (1) TR201807861T4 (forum.php)
UA (1) UA115455C2 (forum.php)
WO (1) WO2014059422A1 (forum.php)
ZA (1) ZA201502349B (forum.php)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6300042B2 (ja) 2012-10-12 2018-03-28 エグゼリクシス, インコーポレイテッド 癌の処置に使用するための化合物の製造方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
IL256299B2 (en) 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
EP3496752B1 (en) 2016-08-12 2022-05-18 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
CN109862917A (zh) 2016-09-29 2019-06-07 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
US20240173329A1 (en) 2021-03-09 2024-05-30 Genentech, Inc. Belvarafenib for use in treatment of brain cancers
KR20230165795A (ko) 2021-04-06 2023-12-05 제넨테크, 인크. 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US6048885A (en) 1994-04-01 2000-04-11 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
DE69826662T2 (de) 1997-07-01 2005-02-17 Warner-Lambert Co. Llc 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
JP2002532414A (ja) 1998-12-15 2002-10-02 ワーナー−ランバート・カンパニー 移植片拒絶反応を防止するためのmek阻害剤の使用
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
KR20010099877A (ko) 1998-12-22 2001-11-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 배합물 화학요법
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
BR9916785A (pt) 1999-01-07 2001-10-23 Warner Lambert Co Tratamento de asma com inibidores mek
EP1140067A1 (en) 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
WO2000042003A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
HK1041697A1 (zh) 1999-01-13 2002-07-19 沃尼尔‧朗伯公司 苯并杂环和它们作为mek抑制剂的用途
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 4′ヘテロアリールジアリールアミン
AP2001002225A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
JP2003504398A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Mek阻害剤を用いた慢性疼痛の治療方法
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
PL352684A1 (pl) 1999-07-16 2003-09-08 Warner-Lambert Company Sposób leczenia chronicznego bólu z użyciem inhibitorów MEK
PL352712A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
AP2003002742A0 (en) 2000-07-19 2003-03-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
IL154507A0 (en) * 2000-08-25 2003-09-17 Warner Lambert Co Process for making n-aryl-anthranilic acids and their derivatives
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
CA2460118A1 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
TW200406203A (en) 2002-03-13 2004-05-01 Array Biopharma Inc N3 alkylated banzimidazole derivatives as MEK inhibitors
PL230179B1 (pl) 2002-03-13 2018-09-28 Array Biopharma Inc N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7314873B2 (en) 2002-06-11 2008-01-01 Merck & Co., Inc. (Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
WO2004078116A2 (en) 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
US7521460B2 (en) 2003-06-20 2009-04-21 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
EP1651214B1 (en) 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
AU2004299198A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AU2005298932B2 (en) * 2004-10-20 2012-03-22 Merck Serono Sa 3-arylamino pyridine derivatives
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
PL1934174T3 (pl) 2005-10-07 2011-09-30 Exelixis Inc Azetydyny jako inhibitory w leczeniu chorób proliferacyjnych
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
AU2007334402B2 (en) * 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
JP6300042B2 (ja) 2012-10-12 2018-03-28 エグゼリクシス, インコーポレイテッド 癌の処置に使用するための化合物の製造方法
CN105992755B (zh) 2014-02-07 2018-07-13 住友化学株式会社 (r)-1,1,3-三甲基-4-氨基茚满的制造方法
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
KR20150067339A (ko) 2015-06-17
MA38085A1 (fr) 2018-08-31
US9771347B2 (en) 2017-09-26
CR20200237A (es) 2020-07-26
EA030613B1 (ru) 2018-08-31
IL238116B (en) 2018-06-28
KR102204520B1 (ko) 2021-01-20
CA2889466C (en) 2021-09-14
AU2013328929A1 (en) 2015-04-30
PL2909188T3 (pl) 2018-08-31
JP2018052973A (ja) 2018-04-05
EP2909188A1 (en) 2015-08-26
SA515360271B1 (ar) 2016-05-19
EP2909188B1 (en) 2018-03-07
MY186549A (en) 2021-07-26
HK1213878A1 (en) 2016-07-15
US20200392104A1 (en) 2020-12-17
US11414396B2 (en) 2022-08-16
PE20151494A1 (es) 2015-11-06
US10793541B2 (en) 2020-10-06
PE20191818A1 (es) 2019-12-27
CN104837826B (zh) 2018-07-27
US10239858B2 (en) 2019-03-26
TR201807861T4 (tr) 2018-06-21
PE20200387A1 (es) 2020-02-24
US20170349569A1 (en) 2017-12-07
MX2020005533A (es) 2020-10-12
CL2015000926A1 (es) 2015-08-28
CR20150245A (es) 2015-11-19
BR112015008113A2 (pt) 2017-07-04
CN108948043A (zh) 2018-12-07
MX2015004660A (es) 2015-08-07
IN2015DN03928A (forum.php) 2015-10-02
AU2013328929B2 (en) 2018-01-04
CA2889466A1 (en) 2014-04-17
US20150210668A1 (en) 2015-07-30
BR112015008113B1 (pt) 2022-05-24
PH12015500785A1 (en) 2015-06-15
HRP20180670T1 (hr) 2018-07-13
UA115455C2 (uk) 2017-11-10
WO2014059422A1 (en) 2014-04-17
CN104837826A (zh) 2015-08-12
SG11201502795VA (en) 2015-05-28
ZA201502349B (en) 2019-12-18
HK1213567A1 (zh) 2016-07-08
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
PH12015500785B1 (en) 2015-06-15
ES2671502T3 (es) 2018-06-06
EA201590700A1 (ru) 2015-09-30
JP6300042B2 (ja) 2018-03-28
SI2909188T1 (en) 2018-07-31
JP2015533175A (ja) 2015-11-19
MX372708B (es) 2020-05-29
NZ706723A (en) 2018-07-27
CN108948043B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MY177344A (en) Compounds and their methods of use
EA201400178A1 (ru) Лечение рака молочной железы
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
MX2013010898A (es) Novedoso derivados de la pirimidina.
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX354024B (es) Uso de array-380 y ar00440993 para el tratamiento de cancer de cerebro.
NZ711192A (en) Process for making benzoxazepin compounds
PH12015501088A1 (en) Dimeric compounds
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2016008259A (es) Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
GEP201706626B (en) Synthesis of (s)-nifuratel
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
PH12014501712B1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
GB201107985D0 (en) Process
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
IN2013MU01113A (forum.php)
GB201209015D0 (en) Novel compounds
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy